user_mobilelogo

We make no claims regarding the medicinal, preventive or curative properties of wolfberries (lycium barbarum). This product is not intended to diagnose, treat, cure, or prevent disease. The wolfberry fruit has been used in traditional Chinese medicine (TCM) for more than 2000 years. Modern scientists have been researching the potential of wolfberries (lycium barbarum) over the past 20 years. Scroll down to see these research articles posted on the National Institutes of Health (NIH.GOV) website.

 

A Pectin From Fruits of Lycium Barbarum L. Decreases β-amyloid Peptide Production Through Modulating APP Processing

2018 Aug 15 Abstract

Here, a pectin LBP1C-2 with the molecular weight of 99.8 kDa was purified from fruits of Lycium barbarum L. Its structure was elucidated as a backbone of alternate 1, 2-linked α-Rhap and 1, 4-linked α-GalpA, with branches of terminal (T) -, 1, 3-, 1, 6- and 1, 3, 6-linked β-Galp, T-, 1, 5- and 1, 3, 5-linked α-Araf and T-linked β-Rhap substituted at C-4 of 1, 2, 4-linked α-Rhap. The cell-based experiments indicated that LBP1C-2 suppressed Aβ42 production in a dose-dependent manner with no cytotoxicity. Further study showed that expression of β-site APP cleaving enzyme 1 (BACE1) was attenuated by LBP1C-2, while expression of ADAM10 was up-regulated by LBP1C-2. Moreover, LBP1C-2 promoted the expression of insulin-degradation enzyme (IDE). These results suggested that LBP1C-2 might be a leading compound for anti-Alzheimer's disease therapy by decreasing Aβ42 production through mediating BACE1 and ADAM10 as well as IDE expression.

https://pubmed.ncbi.nlm.nih.gov/30241864/

Source: U.S. National Library of Medicine 

 

Neuro-protective Mechanisms of Lycium Barbarum

2016 Mar 31 Abstract

Neuronal diseases, including retinal disorders, stroke, Alzheimer's disease, Parkinson's disease and spinal cord injury, affect a large number of people worldwide and cause heavy social and economic burdens. Although many efforts have been made by scientists and clinicians to develop novel drug and healthcare strategies, few of them received satisfactory outcomes to date. Lycium barbarum is a traditional homology of medicine and food in Chinese medicine, with the capability to nourish the eyes, liver and kidneys. Recent studies have also explored its powerful neuro-protective effects on a number of neuronal diseases. In the current review, we collected key recent findings regarding the neuro-protective effects and mechanisms of L. barbarum derivatives, primarily its polysaccharide (LBP) , in some common diseases of the nervous system. A comprehensive comparison with currently available drugs has also been discussed. In general, LBP is a promising neuronal protector with potent ameliorative effects on key pathological events, such as oxidative stress, inflammation, apoptosis and cell death with minimal side effects.

https://pubmed.ncbi.nlm.nih.gov/27033360/

Source: U.S. National Library of Medicine 

 

An Arabinogalactan From Fruits of Lycium Barbarum L. Inhibits Production and Aggregation of Aβ 42

2018 Sep 1 Abstract

The β amyloid (Aβ) induced neurodegeneration is believed to be one of pathological mechanisms of Alzheimer's disease (AD). The inhibition of Aβ production or aggregation is one of the promising therapeutic strategies for anti-AD drug discovery. Here, a homogeneous neutral polysaccharide designated LBP1A1-1 with an average molecular weight of 45.0 kDa was purified from fruits of Lycium barbarum L. Its structure was characterized to possess a backbone of 1, 3-linked β-Galp, 1, 6-linked β-Galp, 1, 4-linked α-Glcp with branches substituted at C-3 position of 1, 6-linked β-Galp or C-6 position of 1, 3-linked β-Galp. The branches contained terminal (T)-linked β-Galp, T-linked α-Araf, T-linked β-Araf, 1, 5-linked α-Araf and T-linked β-Rhap. The in vitro experiments revealed that LBP1A1-1 could inhibit Aβ42 production and impede Aβ42 aggregation in a dose-dependent-manner without cytotoxicity. These results suggested that LBP1A1-1 might have the multiple potential for the treatment of AD.

https://pubmed.ncbi.nlm.nih.gov/29805023/

Source: U.S. National Library of Medicine 

 

An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides

2014 Dec 17 Abstract

Lycium barbarum berries, also named wolfberry, Fructus lycii, and Goji berries, have been used in the People's Republic of China and other Asian countries for more than 2,000 years as a traditional medicinal herb and food supplement. L. barbarum polysaccharides (LBPs) are the primary active components of L. barbarum berries and have been reported to possess a wide array of pharmacological activities. Herein, we update our knowledge on the main pharmacological activities and possible molecular targets of LBPs.

  • Several clinical studies in healthy subjects show that consumption of wolfberry juice improves general wellbeing and immune functions.
  • LBPs are reported to have antioxidative and antiaging properties in different models. LBPs show antitumor activities against various types of cancer cells and inhibit tumor growth in nude mice through induction of apoptosis and cell cycle arrest.
  • LBPs may potentiate the efficacy of lymphokine activated killer/interleukin-2 combination therapy in cancer patients.
  • LBPs exhibit significant hypoglycemic effects and insulin-sensitizing activity by increasing glucose metabolism and insulin secretion and promoting pancreatic β-cell proliferation.
  • They protect retinal ganglion cells in experimental models of glaucoma.
  • LBPs protect the liver from injuries due to exposure to toxic chemicals or other insults.
  • They also show potent immunoenhancing activities in vitro and in vivo.
  • Furthermore, LBPs protect against neuronal injury and loss induced by β-amyloid peptide, glutamate excitotoxicity, ischemic/reperfusion, and other neurotoxic insults.
  • LBPs ameliorate the symptoms of mice with Alzheimer's disease and enhance neurogenesis in the hippocampus and subventricular zone, improving learning and memory abilities.
  • They reduce irradiation- or chemotherapy-induced organ toxicities.
  • LBPs are beneficial to male reproduction by increasing the quality, quantity, and motility of sperm, improving sexual performance, and protecting the testis against toxic insults.
  • Moreover, LBPs exhibit hypolipidemic, cardioprotective, antiviral, and antiinflammatory activities.

There is increasing evidence from preclinical and clinical studies supporting the therapeutic and health-promoting effects of LBPs, but further mechanistic and clinical studies are warranted to establish the dose-response relationships and safety profiles of LBPs.

https://pubmed.ncbi.nlm.nih.gov/25552899/

Source: U.S. National Library of Medicine 

 

*These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure, or prevent disease.